NEWSROOMAllPress ReleasesNewsAll March 6, 2024 Onchilles Pharma Announces Two Presentations of New Preclinical Data for N17350 and N17465 at AACR 2024 January 5, 2024 Drug Target Review: Transforming Cancer Treatment for Greatest Impact November 3, 2023 Onchilles Pharma Presents at SITC 2023 New Preclinical Data for N17350, a Potential Pan-Cancer Therapeutic September 27, 2023 Onchilles Pharma Announces Presentation of Data for N17350 Program at SITC 2023 April 19, 2023 Onchilles Pharma Presents at AACR 2023 New Preclinical Data on N17350, a First-in-Class Immuno-Oncology Drug Candidate with Broad, Potent, and Direct Tumor Killing ActivityPress Releases November 3, 2023 Onchilles Pharma Presents at SITC 2023 New Preclinical Data for N17350, a Potential Pan-Cancer Therapeutic September 27, 2023 Onchilles Pharma Announces Presentation of Data for N17350 Program at SITC 2023 April 19, 2023 Onchilles Pharma Presents at AACR 2023 New Preclinical Data on N17350, a First-in-Class Immuno-Oncology Drug Candidate with Broad, Potent, and Direct Tumor Killing Activity March 14, 2023 Onchilles Pharma Announces Presentation of Preclinical Data for N17350 at AACR 2023 December 12, 2022 Onchilles Pharma Nominates First Drug Development Candidate Targeting Neutrophil Biology for the Treatment of CancerNews January 5, 2024 Drug Target Review: Transforming Cancer Treatment for Greatest Impact June 20, 2021 SDBJ: Onchilles Pharma Raises $7M for Targeted Cancer Therapy June 15, 2021 BioWorld: Onchilles looks for cancer’s Achilles heel with a $7M series A June 10, 2021 Onchilles Pharma Raises $7 Million Series A to Advance Drug Candidates to Activate Newly Discovered Broad-Acting Anticancer Pathway June 10, 2021 Could neutrophils be the secret to cancer’s Achilles’ heel?
